The latest lymphoma news
FDA approves epcoritamab-bysp for follicular lymphoma indications
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp with lenalidomide and rituximab for…
Browsing: Lymphoma
ASH 2025: New combination approach aims to make CAR T more durable in lymphoma
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell…
New combination therapy shows promise for aggressive lymphoma resistant to immunotherapy
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to…
Antibody-cancer drug combo shows promise against aggressive lymphoma
Antibodies coupled with a natural compound found in soil microbes proved a powerful combination against…
Study demonstrates drug combination is well tolerated, safe and effective for patients with aggressive blood cancer
Using real-world data, Mass General Brigham researchers reveal how the combination of two blood cancer…
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix with lenalidomide and rituximab…
Thousands of blood cancer patients could benefit from new drug combination
Thousands of patients with a common type of blood cancer could benefit from a new…
Enhanced CAR T cell therapy offers new strategy for lymphoma
A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients…
A new CAR-T therapy achieves positive results in a high proportion of patients with a refractory type of lymphoma
Researchers at the Sant Pau Research Institute (IR Sant Pau), in collaboration with the Hospital…
Genomic analysis provides insight into underpinnings of new treatment combination for deadly, Asian-prevalent lymphoma
A multinational research team of clinicians and scientists from South Korea and Singapore has published…